[{"id":"442691c8-a704-4880-a6a9-2ddbd5bc9513","acronym":"","url":"https://clinicaltrials.gov/study/NCT06258629","created_at":"2024-02-14T16:26:57.150Z","updated_at":"2024-07-02T16:35:19.443Z","phase":"","brief_title":"Prognostic Value of \"CD200\" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality","source_id_and_acronym":"NCT06258629","lead_sponsor":"Sohag University","biomarkers":" CD200","pipe":"","alterations":" ","tags":["CD200"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/15/2024","start_date":" 02/15/2024","primary_txt":" Primary completion: 02/06/2025","primary_completion_date":" 02/06/2025","study_txt":" Completion: 02/06/2025","study_completion_date":" 02/06/2025","last_update_posted":"2024-02-14"},{"id":"6817ade8-2b47-4eca-9afd-b28ec20d68bb","acronym":"MARSUN","url":"https://clinicaltrials.gov/study/NCT06006117","created_at":"2023-08-23T16:10:50.844Z","updated_at":"2024-07-02T16:35:35.484Z","phase":"Phase 3","brief_title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","source_id_and_acronym":"NCT06006117 - MARSUN","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" CD200 • ITGAX","pipe":" | ","alterations":" CD200 expression","tags":["CD200 • ITGAX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • bendamustine • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 09/05/2023","start_date":" 09/05/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2023-09-27"},{"id":"2bb7d6c9-0473-46c7-9460-ae9487c6e000","acronym":"","url":"https://clinicaltrials.gov/study/NCT04679480","created_at":"2021-01-19T20:46:22.519Z","updated_at":"2024-07-02T16:36:00.949Z","phase":"Phase 2","brief_title":"Anti-PD1-antibody and Pulsed HHI for Advanced BCC","source_id_and_acronym":"NCT04679480","lead_sponsor":"Reinhard Dummer","biomarkers":" CD8 • PD-1 • CD4 • CD200 • FOXP3","pipe":" | ","alterations":" PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression","tags":["CD8 • PD-1 • CD4 • CD200 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-1 expression • BCL2 expression • CD20 expression • CD200 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc) • Odomzo (sonidegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-04"},{"id":"13e31fc7-6242-40ee-99d8-2f2a2731674e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05512104","created_at":"2022-08-23T14:55:30.941Z","updated_at":"2024-07-02T16:36:05.049Z","phase":"","brief_title":"Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression","source_id_and_acronym":"NCT05512104","lead_sponsor":"Assiut University","biomarkers":" NCAM1 • CD200","pipe":" | ","alterations":" NCAM1 expression","tags":["NCAM1 • CD200"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NCAM1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2022-08-23"},{"id":"7f239492-f11c-4e34-b238-37cd373c3cec","acronym":"","url":"https://clinicaltrials.gov/study/NCT03766763","created_at":"2021-01-18T18:38:18.690Z","updated_at":"2024-07-02T16:36:06.608Z","phase":"Phase 2","brief_title":"Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A","source_id_and_acronym":"NCT03766763","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" CD20 • CD200","pipe":" | ","alterations":" CD20 positive • CD38 positive","tags":["CD20 • CD200"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 01/22/2022","primary_completion_date":" 01/22/2022","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2022-07-27"}]